Equities

Formosa Laboratories Inc

4746:TAI

Formosa Laboratories Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TWD)99.40
  • Today's Change6.20 / 6.65%
  • Shares traded3.64m
  • 1 Year change+12.95%
  • Beta--
Data delayed at least 20 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of TWD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments2,5101,6311,093
Total Receivables, Net1,024827803
Total Inventory1,5971,6021,639
Prepaid expenses1098980
Other current assets, total2.022.243.81
Total current assets5,2444,1513,619
Property, plant & equipment, net6,0955,9785,986
Goodwill, net313131
Intangibles, net174192217
Long term investments1,9502,2542,083
Note receivable - long term------
Other long term assets6.537.908.00
Total assets13,63612,75112,017
LIABILITIES
Accounts payable203187204
Accrued expenses486451394
Notes payable/short-term debt1,5341,5001,177
Current portion long-term debt/capital leases472641313
Other current liabilities, total546362298
Total current liabilities3,2413,1422,386
Total long term debt2,0571,6591,930
Total debt4,0633,8003,420
Deferred income tax242524
Minority interest639276207
Other liabilities, total10312975
Total liabilities6,0655,2304,622
SHAREHOLDERS EQUITY
Common stock1,2031,2031,203
Additional paid-in capital3,5523,5143,503
Retained earnings (accumulated deficit)2,8102,8092,640
Treasury stock - common------
Unrealized gain (loss)204.3458
Other equity, total(14)(10)(8.57)
Total equity7,5717,5217,395
Total liabilities & shareholders' equity13,63612,75112,017
Total common shares outstanding120120120
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.